Trial Profile
Retrospective Review of Valganciclovir Efficacy in Preventing CMV Disease in D+/R- Liver Transplant Recipients - A Non-Interventional Program
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 May 2019
Price :
$35
*
At a glance
- Drugs Valganciclovir (Primary)
- Indications Cytomegalic inclusion disorders
- Focus Therapeutic Use
- Sponsors Roche
- 24 Feb 2014 New trial record